Legius syndrome
Legius syndrome | |
---|---|
Classification and external resources | |
OMIM | 611431 |
DiseasesDB | 34916 |
Legius syndrome (LS) is an autosomal dominant condition characterized by cafe au lait spots.[1] It was first described in 2007 and is often mistaken for Neurofibromatosis type I (NF-1). It is caused by mutations in the SPRED1 gene.[2][3][4] It is also known as Neurofibromatosis Type 1-like syndrome (NFLS). The syndrome is named after Eric Legius, Professor at the KU Leuven. It is a RASopathy.
Symptoms
Nearly all patients show multiple Café au lait spots. Other symptoms may include:
- Freckles in the armpits and/or groin
- Lipomas
- Macrocephaly
- Learning disabilities
- ADHD
- Developmental delay[5]
Features common in neurofibromatosis - Lisch nodules, bone abnormalities, neurofibromas, optic pathway gliomas and malignant peripheral nerve sheath tumors - are absent in this condition.
Diagnosis
Genetic testing is necessary to identify the syndrome. The test checks for loss of function mutations in the SPRED1 gene.
Confusion with Neurofibromatosis Type I
The symptoms of Legius syndrome and NF-1 are very similar. This is the reason why the two are easily confused. A genetic test is often the only way to make sure a person has LS and not NF-1. The similarity of symptoms stem from the fact that the different genes affected in the two syndromes code for proteins that carry out a similar task in the same reaction pathway.
An important difference is the absence of tumor growths (Lisch nodules and Neurofibromas which are common in NF-1) in LS.[5]
Because of this difference, Legius syndrome is often seen as the less severe of the two syndromes.
Disease Database
See also
References
- ↑ "Legius syndrome", Genetics Home Reference, National Institutes of Health
- ↑ "SPRED1", Genetics Home Reference, National Institutes of Health
- ↑ "Legius Syndrome Often Mistaken for Neurofibromatosis Type 1", by Allison Gandley, November 18, 2009, Medscape
- ↑ "Legius Syndrome (SPRED1) Sequencing & (NF1) Sequencing Exon 22 (Exon 17)", May 2010, ARUP Laboratories
- ↑ 5.0 5.1 , Pagon RA, Bird TD, Dolan CR, et al.
|
|